^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Fruzaqla (fruquintinib) (VEGFR inhibitor) + Aibining (geptanolimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase ib trial of assessing the safety and preliminary efficacy of a combination therapy of geptanolimab (GB 226) plus fruquintinib in patients with metastatic colorectal cancer (mCRC)
Published date:
05/19/2021
Excerpt:
Patients were given geptanolimab...and fruquintinib...15 patients were enrolled: 1 with MSI-H, 12 with MSS, and 2 with MS unknown. In all evaluable patients, the overall ORR was 26.7% (4/15, 3 confirmed PR, 1 unconfirmed PR), and the ORR was 33.3% (2/6) in the RP2D group. The DCR for all evaluable patients was 80%, and the median PFS (mPFS) was 7.33 months (95% CI: 1.91 – NE). The combination of geptanolimab and fruquintinib had manageable safety profiles and encouraging anti-tumor activity in mCRC patients.
DOI:
10.1200/JCO.2021.39.15_suppl.e15551
